{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T02:12:56Z","timestamp":1649124776389},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00210-017-1425-9","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T19:14:19Z","timestamp":1505330059000},"page":"1173-1175","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Siglec-8 as mast cell selective target: developing paradigms amidst inconvenient truths"],"prefix":"10.1007","volume":"390","author":[{"given":"Gerhard J.","family":"Molderings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"1425_CR1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","volume":"48","author":"LB Afrin","year":"2016","unstructured":"Afrin LB, Butterfield JH, Raithel M, Molderings GJ (2016) Often seen, rarely recognized: mast cell activation disease\u2014a guide to diagnosis and therapeutic options. Ann Med 48:190\u2013201","journal-title":"Ann Med"},{"key":"1425_CR2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00251-014-0768-3","volume":"66","author":"B Haenisch","year":"2014","unstructured":"Haenisch B, Fr\u00f6hlich H, Herms S, Molderings GJ (2014) Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease. Immunogenetics 66:287\u2013297","journal-title":"Immunogenetics"},{"key":"1425_CR3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","volume":"135","author":"T Kiwamoto","year":"2012","unstructured":"Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS (2012) Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 135:327\u2013336","journal-title":"Pharmacol Ther"},{"key":"1425_CR4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2014.09.001","volume":"93","author":"GJ Molderings","year":"2015","unstructured":"Molderings GJ (2015) The genetic basis of mast cell activation disease\u2014looking through a glass darkly. Crit Rev Oncol Hematol 93:75\u201389","journal-title":"Crit Rev Oncol Hematol"},{"key":"1425_CR5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.trsl.2016.01.001","volume":"174","author":"GJ Molderings","year":"2016","unstructured":"Molderings GJ (2016) Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features. Transl Res 174:86\u201397","journal-title":"Transl Res"},{"key":"1425_CR6","doi-asserted-by":"crossref","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","volume":"8","author":"GJ Molderings","year":"2013","unstructured":"Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, N\u00f6then MM (2013) Familial occurrence of systemic mast cell activation disease. PLoS One 8:e76241","journal-title":"PLoS One"},{"key":"1425_CR7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","volume":"389","author":"GJ Molderings","year":"2016","unstructured":"Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB (2016) Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedeberg's Arch Pharmacol 389:671\u2013694","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"1425_CR8","doi-asserted-by":"publisher","unstructured":"O'Sullivan JA, Carroll DJ, Cao Y, Salicru AN, Bochner BS (2017) Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. J Allergy Clin Immunol. \nhttps:\/\/doi.org\/10.1016\/j.jaci.2017.06.028","DOI":"10.1016\/j.jaci.2017.06.028"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-017-1425-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-017-1425-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-017-1425-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:06:59Z","timestamp":1507162019000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-017-1425-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1007\/s00210-017-1425-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]}}}